A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

NCT07003074 · clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
642
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.